#TorqueTenoVirus
Successful trial ✅️

An international team coordinated by #MedUniVienna demonstrated in a #clinicaltrial that #TorqueTenovirus-guided dosing of #immunosuppressants in #kidneytransplant recipients is safe.

More about the @ttvguidetx.bsky.social​ study coordinated by @gregorbond.bsky.social​! ⬇️
Biomarker-guided immunosuppression following kidney transplantation successfully tested
Further details!
www.meduniwien.ac.at
June 8, 2026 at 7:13 AM
might TTMD and TTM virus 🦠
complement TT virus guided
immune monitoring? 🧬🔍

great work from Rome 🇮🇹

#ttvguide
www.mdpi.com/1422-0067/26...
Assessment of Torquetenominivirus (TTMV) and Torquetenomidivirus (TTMDV) as Complementary Biomarkers to Torquetenovirus (TTV)
Recent studies have identified Torquetenovirus (TTV) as a promising biomarker of immune competence, particularly in assessing the vaccine response of solid organ transplant (SOT) recipients. However, ...
www.mdpi.com
February 19, 2025 at 8:45 AM
🗞️ New paper out on Torquetenominivirus and Torquetenomidivirus as Complementary Biomarkers to Torquetenovirus (#TTV). Partners in Italy have described associations with Torquetenominivirus (TTMV) and Torquetenomidivirus (TTMDV) with SARS-CoV-2 Vaccination response. www.mdpi.com/1422-0067/26...
Assessment of Torquetenominivirus (TTMV) and Torquetenomidivirus (TTMDV) as Complementary Biomarkers to Torquetenovirus (TTV)
Recent studies have identified Torquetenovirus (TTV) as a promising biomarker of immune competence, particularly in assessing the vaccine response of solid organ transplant (SOT) recipients. However, ...
www.mdpi.com
February 19, 2025 at 7:15 AM
#CEoT2025 has begun! See you at our booth.

We know your time is valuable. If you find a spare moment during your trip, explore our resource center.

View our #TTV webinar presented by Gregor Bond, MD, PhD. WATCH: www.eurofins-viracor.com/resource-cen...

#TorqueTenoVirus @gregorbond.bsky.social
February 27, 2025 at 7:09 PM
TTVのウイルス量が免疫療法後の免疫機能回復を示す新たなバイオマーカーとして注目。がん患者のTTVレベルが治療後低下し、健康者と近づく結果は興味深い。免疫状態のモニタリングに応用可能な可能性を示唆する研究。#免疫療法 #バイオマーカー
Analysis of Torquetenovirus DNA levels in NSCLC patients treated with immune checkpoint inhibitors
In recent years, Torquetenovirus (TTV) load has emerged as a potential biomarker of immune competence across various clinical contexts, albeit its significance in cancer patients undergoing immunotherapy remains largely unexplored. This study aimed to investigate the level of TTV viral load in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs). A total of 64 NSCLC patients were enrolled. Serum TTV DNA levels were quantified by real-time PCR at baseline (T0) and after three months of ICI therapy (T1). As control, TTV levels were also measured in a cohort of healthy donors at a single time point. Statistical analyses were performed to compare TTV copy numbers across groups and time points. At baseline, cancer patients exhibited significantly higher TTV viral loads than healthy donors, consistent with an immunocompromised status. Following ICI treatment, a significant decline in TTV levels was observed in the oncologic cohort, reaching values comparable to those of healthy individuals, with a more pronounced decrease observed in patients responsive to therapy. This study provides the first evidence that TTV viral load decreases following immunotherapy in NSCLC patients, potentially reflecting a restoration of immune competence. These findings support the hypothesis that TTV monitoring could serve as a surrogate marker of immune function during ICI treatment. Further large-scale, longitudinal studies are warranted to validate its clinical meaning in oncologic settings.
journals.plos.org
May 16, 2026 at 1:53 AM
I wouldn't say it reflects infection rate.
Otherwise there might be a million Torquetenovirus publications a year.
It is reflective of global impact, but reaction was part of the impact.
January 13, 2025 at 8:52 PM
We are decoding immune balance with data-driven insight, using Torque Teno Virus to better understand the net state of immunosuppression.

Presented by: Steve Kleiboeker, DVM, PhD

#TorqueTenoVirus #InnovationTheater
February 27, 2026 at 4:16 PM
Risk-stratify your solid organ transplant recipients with TTViWATCH™. How? READ👉 www.eurofins-viracor.com/our-testing/...

Our groundbreaking TTV qPCR assay empowers clinicians to monitor infection and rejection risks in transplant recipients.

#ESOT2025 #TTV #TorqueTenoVirus #ViracorTTV #TTVirus
July 3, 2025 at 3:16 PM
Meet the SCIENTISTS of Eurofins Viracor at #CEoT25. We have a lot going on at #CEoT!

⚕️ Innovation Theater
⚕️ Meet the Scientists
⚕️ Educational Dinner
⚕️ Plush Kidney Giveaway

🗓️ Feb 27 - Mar 1, 2025

INFO: www.eurofins-viracor.com/news-and-eve...

#TorqueTenoVirus #InfectiousDisease #NephSky #IDsky
February 21, 2025 at 7:27 PM
Save the date for the Cutting Edge of Transplantation meeting this year. #CEoT2025

🗓️ FEB 27 – MAR 1 | Scottsdale, AZ

🔎 Streamlining Transplant Diagnostics: Rejection Biomarkers | ID Management | Drug Monitoring

LEARN 🌐 www.eurofins-viracor.com/clinical/our...

#TorqueTenoVirus #IDsky #CEoT
February 10, 2025 at 4:21 PM
Unraveling the complex web of rectal infections and the microbiome in MSM 🧬🔬🩺 www.news-medical.net/news/2024041...
Unraveling the complex web of rectal infections and the microbiome in MSM
Study delves into the relationships between various sexually transmitted infections, including Neisseria gonorrhoeae, Chlamydia trachomatis, Torquetenovirus, and high-risk HPV, and their effects on th...
www.news-medical.net
April 11, 2024 at 12:43 AM